The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer.
 
Mihaela Aldea
Consulting or Advisory Role - Viatris
Research Funding - Amgen (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Sandoz
 
Arianna Marinello
No Relationships to Disclose
 
Isabelle Monnet
Travel, Accommodations, Expenses - oxyvie; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Takeda
 
Hortense de Saint Basile
No Relationships to Disclose
 
Sophie Cousin
Honoraria - AstraZeneca; MSD Oncology; Sanofi; Takeda
Consulting or Advisory Role - Janssen Oncology
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer; Takeda
 
Michaël Duruisseaux
No Relationships to Disclose
 
Antonio Calles
No Relationships to Disclose
 
Giulio Metro
No Relationships to Disclose
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Guardant Health; NanoString Technologies; Pfizer; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; Novartis; Novartis; Pfizer; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Celgene; Roche/Genentech; Sanofi
 
Giacomo Massa
No Relationships to Disclose
 
Patricia Gomez
No Relationships to Disclose
 
Fabrizio Tabbò
No Relationships to Disclose
 
Alessandro Russo
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; MSD; Novartis; Pfizer; Roche
 
Vincent Fallet
No Relationships to Disclose
 
Colin R Lindsay
Honoraria - Amgen
Consulting or Advisory Role - Amgen; cbpartners
Research Funding - Revolution Medicines (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen
 
Emilio Bria
No Relationships to Disclose
 
Anna Eisert
No Relationships to Disclose
 
Florian Guisier
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda; Viatris
Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi
Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD; Takeda
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Janssen; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Hedera Dx (Inst); Janssen (Inst); MSD (Inst); Roche (Inst); Sanofi/Aventis (Inst); Springer Healthcare Ltd (Inst)
Consulting or Advisory Role - Abbvie (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CureVac (Inst); Da voltera (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Genmab (Inst); Immunocore (Inst); Janssen (Inst); Lilly (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst); Taiho Oncology (Inst); Turning Point Therapeutics (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Enliven Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)